Resultados globales: 1 registros encontrados en 0.02 segundos.
Artículos, Encontrados 1 registros
Artículos Encontrados 1 registros  
1.
12 p, 435.5 KB Phase 1 study of capmatinib in MET-positive solid tumor patients : Dose escalation and expansion of selected cohorts / Bang, Yung-Jue (Seoul National University College of Medicine) ; Su, Wu-Chou (National Cheng Kung University Hospital) ; Schuler, Martin (University Duisburg-Essen and German Cancer Consortium (DKTK)) ; Nam, Do-Hyun (Samsung Medical Center) ; Lim, Wan Teck (National Cancer Centre) ; Bauer, Todd M. (PLLC) ; Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Poon, Ronnie Tung Ping (Queen Mary Hospital) ; Hong, David (University of Texas/MD Anderson Cancer Center) ; Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ; Akimov, Mikhail (Novartis Pharma AG) ; Ghebremariam, Samson (Novartis Pharmaceuticals Corporation) ; Zhao, Sylvia (China Novartis Institutes for Biomedical Research) ; Giovannini, Monica (Novartis Pharmaceuticals Corporation) ; Ma, Brigette (The Chinese University of Hong Kong)
Capmatinib is an oral, ATP-competitive, and highly potent, type 1b MET inhibitor. Herein, we report phase 1 dose-escalation results for capmatinib in advanced MET-positive solid tumor patients and dose expansion in advanced non-lung tumors. [...]
2019 - 10.1111/cas.14254
Cancer Science, Vol. 111 (december 2019) , p. 536-547  

Vea también: autores con nombres similares
1 Ghebremariam, S.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.